Delamanid (as part of a longer oral regimen)
Treatment for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: 100mg twice daily for 24 weeks
Effectiveness
75%
Safety Score
65%
Clinical Trials
25
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
100mg twice daily for 24 weeks
Time to Effect
2-3 months for significant clinical improvement
Treatment Duration
Delamanid component 6-9 months, total regimen 9-18 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
82%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$4,000
Side Effect Mgmt:$2,500
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
9
Outcome-Based Costs
Cost per Responder
$62,000
Cost per Remission
$62,000
Comparison vs Older, longer MDR-TB regimens without Delamanid
Cost Difference
+$3,000/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Delamanid (as part of a longer oral regimen) Outcomes
for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+75%
Common Side Effects
QT prolongation
+10%
Headache
+20%
Nausea
+12%
Peripheral neuropathy
+7%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov